In his role as Freenome’s Chief Scientific Officer, Jimmy is responsible for scientific strategy, research operations, and growth of the company’s world-class scientific team. He brings a proven record of translating cutting-edge research into commercial success, with a focus on the development and launch of blood-based assays for cancer monitoring and detection of molecular residual disease.

Prior to joining the private sector, as Chief Scientific Officer for Oncology at Natera, the global genomic diagnostics company, Jimmy led the intramural clinical genomics program at the National Cancer Institute at the National Institutes of Health. At Johns Hopkins University and Washington University in St. Louis, he spearheaded the computational analyses of the first-ever exome sequencing studies in multiple cancer types.

Jimmy holds an M.D. and a Ph.D. in Cellular and Molecular Medicine from Johns Hopkins School of Medicine, as well as a Master of Health Sciences in Bioinformatics from Johns Hopkins School of Public Health. As an undergraduate at Yale University, he majored in Cognitive Science and Molecular Biophysics & Biochemistry. Jimmy was a 2016 Senior TED Fellow and is the Founder and President of the Rare Genomics Institute.